News

Home>News
News2020-07-17T11:41:26-04:00
Oct 42023

Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)

October 4th, 2023|Categories: Investor News, Medical, News, Press Releases|Tags: , , , , , , , |

Jackson Center, PA October 4, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase and 52.3% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group. Neuron Specific Enolase (NSE) ...

Sep 202023

Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts

September 20th, 2023|Categories: Investor News, Medical, News, Press Releases|Tags: , , , , |

Jackson Center, PA September 20, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI).  The initial focus will be on accelerating and fine-tuning Halberd’s proprietary nasal spray for suppressing the effects of traumatic brain injury (TBI).  In addition, consistent with the government request, this will include rapid detection and ...

Sep 62023

Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)

September 6th, 2023|Categories: Featured, Investor News, Medical, News, Press Releases|Tags: , , , |

Anecdotal Results of Halberd’s Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers Jackson Center, PA September 6, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd’s patent-pending nasal spray to mitigate the effects of TBI. Anecdotal data in preliminary testing reveals a 20% reduction in Neuron Specific Enolase and a 50% ...

Aug 222023

Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)

August 22nd, 2023|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , , , |

Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product Jackson Center, PA August 22, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects.  This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray’s ability to mitigate the effects of traumatic brain injury (TBI).  The ...

Aug 142023

Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses

August 14th, 2023|Categories: Featured, Investor News, News|Tags: , , , , , |

Scientific Paper Presented at Research Symposium Jackson Center, PA August 14, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi State University Shackouls Honors College Summer Undergraduate Research Symposium, on August 2, titled “MODEL FOR THERAPEUTIC DEVELOPMENT IN TRAUMATIC BRAIN ...

Jul 202023

Halberd Corporation 2Q23 CEO Letter

July 20th, 2023|Categories: Featured, Investor News, Update Letter|Tags: , |

Jackson Center, PA, July 20, 2023 -- Halberd Corporation (OTC: HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases. 2nd QUARTER 2023 ACHIEVEMENTS Mississippi State University (MSU) is well on their way in testing Halberd’s patent-pending nasal spray to mitigate the neurological effects resulting from traumatic brain injuries (TBI). By directly targeting the ...

Go to Top